What is your current role on AMYPAD?
In October, 2017, I recently joined as co leader WP4 – Risk stratification: Natural history and enrichment strategies.
What is your overall vision?
My vision is aligned with that of the protocol goals and objectives: to characterize the role of quantitative amyloid PET as prognostic biomarker in the AD spectrum focusing on presymptomatic and prodromal phases prior to the onset of dementia. The aim of this study is to evaluate the additional value of quantitative amyloid imaging analysis for modelling and assessing AD dementia risk in individuals without dementia, compared to a range of existing cognitive, imaging, laboratory and genetic biomarkers.
What do you find most challenging about the project?
The scientific goals/objectives are challenging and will provide key important insights for the AD research community. The key goals of the study include:
1)To predict cognitive decline based on quantitative PET amyloid imaging measures, with or without other biomarkers eg CSF, genetic, neuroimaging etc
2) To predict brain atrophy based on quantitative PET amyloid imaging measures, with or without other biomarkers.